Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Replimune GroupREPL +1.25%27 Debt-to-EBITDA is -0.40 as of Mar. 2026. GuruFocus rates REPL with a GF Score™ of 27/100. The stock has 4 warning signs investors should review. Among 297 Biotechnology companies, Replimune Group ranks worse than 336700% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Replimune Group's Debt-to-EBITDA or its related term are showing as below:
REPL'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.83 Med: -0.37 Max: -0.29
Current: -0.37
During the past 10 years, the highest Debt-to-EBITDA Ratio of Replimune Group was -0.29. The lowest was -0.83. And the median was -0.37.
REPL's Debt-to-EBITDA is ranked worse than 100% of 297
companies
in the Biotechnology industry
Industry Median: 1.16
vs REPL: -0.37
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Replimune Group Debt-to-EBITDA Related Terms
Replimune Group Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Replimune Group's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
REPL vs ANNX, SLDB, ABUS: Debt-to-EBITDA Comparison
For the Biotechnology subindustry, Replimune Group's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Replimune Group Debt-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Replimune Group's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Replimune Group's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Replimune Group (REPL) has a Debt-to-EBITDA of -0.40 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Replimune Group. According to the industry distribution chart, Replimune Group ranks #999999 out of 297 companies in the Biotechnology industry.
Is Replimune Group's Debt-to-EBITDA too high?
Replimune Group's current Debt-to-EBITDA is -0.40. Based on the distribution chart, Replimune Group ranks #999999 out of 297 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Replimune Group has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Replimune Group's Debt-to-EBITDA compare to ANNX and SLDB?
According to the Biotechnology industry distribution chart, Replimune Group ranks #999999 out of 297 companies for Debt-to-EBITDA. This places Replimune Group in the lower half of its industry. The industry median Debt-to-EBITDA is 1.16. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Biotechnology company?
The median Debt-to-EBITDA among Biotechnology companies is 1.16, based on 297 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Replimune Group. For the Biotechnology industry, the median Debt-to-EBITDA is 1.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Replimune Group's current Debt-to-EBITDA is -0.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Replimune Group stock overvalued right now?
Replimune Group (REPL) has a current Debt-to-EBITDA of -0.40. The current Debt-to-EBITDA is -0.40. Replimune Group's overall GF Score™ is 27/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Replimune Group (REPL), the current Debt-to-EBITDA is -0.40 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.
27GF Score
Get the complete analysis for REPL
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
REPL has been successfully added to your 
